stockportfolio.pro
Stocks / IMVT vs KYMR
IMVT vs KYMR
Immunovant, Inc. and Kymera Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Immunovant, Inc. (IMVT) | Kymera Therapeutics, Inc. (KYMR) | |
|---|---|---|
| Market cap | $6.6B | $6.7B |
| Revenue (latest FY) | $0 | $39.21M |
| Net income (latest FY) | $-505.61M | $-311.35M |
| Revenue growth (5y CAGR) | — | 2.9% |
| Net margin | — | -794.0% |
| Return on equity | -59.3% | -19.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IMVT — free Open KYMR — freeFrequently asked questions
Which is bigger, IMVT or KYMR?
Kymera Therapeutics, Inc. is larger by market capitalization — $6.7B versus $6.6B.
Which grows faster, IMVT or KYMR?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.